ArticleFrontiers in immunology2022
Clinical Features, Treatment, and Prognostic Factors in Neuronal Surface Antibody-Mediated Severe Autoimmune Encephalitis.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-Analysis of the Recurrence of Autoimmune Encephalitis.Annals of clinical and translational neurology · 2026Pooled it
- Ofatumumab Therapy and Long-Term Seizure Outcomes of Patients With Relapsing Anti-NMDA Receptor Encephalitis.Annals of clinical and translational neurology · 2026Article
- Repeat Lumbar Puncture in Adults With Encephalitis: Patient Characteristics, Cerebrospinal Fluid Dynamics, and Diagnostic Yield.Open forum infectious diseases · 2026Article
- Case Report: Efficacy of efgartigimod for autonomic dysfunction in patients with autoimmune glial fibrillary acidic protein astrocytopathy: a case series of 3 patients.Frontiers in immunology · 2026Article
- Effectiveness of Anti-CD20 B cells depleting therapy versus conventional treatment in severe Anti-N-methyl-d-aspartate receptor encephalitis: A real-world multi-center prospective cohort study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Immunotherapy for autoimmune encephalitis.Cell death discovery · 2025Review
- Detection of antibodies in suspected autoimmune encephalitis diseases using machine learning.Scientific reports · 2025Article
- Development and Validation of a Risk Score for Predicting ICU Admission in Adults with New-Onset Encephalitis.Neurocritical care · 2025Article
- Abnormal CSF-Specific OCBs in Neuronal Surface Antibody-Associated Autoimmune Encephalitis Differentiating from Viral Encephalitis.Journal of inflammation research · 2025Article
- Prediction model for severe autoimmune encephalitis: a tool for risk assessment and individualized treatment guidance.Frontiers in neurology · 2025Article
- Clinical spectrum and long-term outcomes of antibody-negative severe autoimmune encephalitis: a retrospective study.Frontiers in immunology · 2025Article
- Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report.Frontiers in immunology · 2025Article
- Association of systemic inflammatory factors with clinical outcomes in patients with autoimmune encephalitis at different clinical stages.Frontiers in immunology · 2025Article
- Prediction of Seropositivity in Suspected Autoimmune Encephalitis by Use of Radiomics: A Radiological Proof-of-Concept Study.Diagnostics (Basel, Switzerland) · 2024Article
- Autoimmune encephalitis in a resource-limited public health setting: a case series analysis.Arquivos de neuro-psiquiatria · 2024Article
- Validation of the clinical assessment scale for autoimmune encephalitis in a severe autoimmune encephalitis cohort.Frontiers in immunology · 2024Article
- [Diagnostic value of low versus high titers of MOG-IgG and their clinical implications in myelin oligodendrocyte glycoprotein antibody-associated disease: a retrospective singlecenter study].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Long-term efficacy and safety of different corticosteroid courses plus mycophenolate mofetil for autoimmune encephalitis with neuronal surface antibodies without tumor.Frontiers in immunology · 2023Article
- Predictive value of the neutrophil-to-lymphocyte ratio for treatment response in patients diagnosed with definite or probable autoimmune encephalitis/encephalopathy.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to determine the clinical characteristics and evaluate the efficacy of immunotherapy and the long-term prognosis of severe autoimmune encephalitis (AE) in China. Methods: Clinical features, laboratory or radiological findings, and treatment outcomes of 60 severe patients with AE from January 1, 2014, to December 31, 2020, were collected. Continuous variables were compared using the Results: The median age of symptom onset was 35 years. Tumors were identified in 23.3% of patients, and 36/60 (60%) patients responded to first-line immunotherapy. Second-line immunotherapy was implemented in 26/60 (43.3%) patients. A significant clinical benefit was observed in 19/26 (73.1%) patients treated with lower dosage rituximab; seven patients were still refractory and received bortezomib as an add-on therapy. During the last follow-up, 48/60 (80%) patients achieved good outcomes (mRS, 0-2), and 10 died. Seventeen patients experienced relapses. A high CD19 Conclusions: Patients with severe AE were in critical condition at baseline but could be salvaged after effective rescue immunotherapy. A lower dosage of rituximab could be an optimal option for severe AE. CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.